

Data Sharing Statement

Conroy. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. *JAMA Oncol*. Published September 01, 2022.

doi:10.1001/jamaoncol.2022.3829

Data

Data available: Yes

Data types: Other (please specify)

Additional Information: The study data will be available following publication to researchers wishing to do meta-analyses or for other research proposals, subject to approval and agreement from the study sponsor (R&D Unicancer). Requests should be made to I-monard@unicancer.fr.

How to access data: Requests should be made to I-monard@unicancer.fr.

When available: With publication

Supporting Documents

Document types: Other (please specify)

Additional Information: Informed consent form will be made available on request to I-monard@unicancer.fr.

How to access documents: Informed consent form will be made available on request to I-monard@unicancer.fr.

When available: With publication

Additional Information

Who can access the data: Any researcher with agreement from the study sponsor (R&D Unicancer).

Types of analyses: Requests should be made to I-monard@unicancer.fr.

Mechanisms of data availability: With Principal investigator support